

615.32:547.814.5.

- 2
1 : : , : : : " : : .
2 : : , : : : " : : .
1 : : " : : : " : : .
: : : , : : : , : : .
- 1
2 « ,
» ,
-

5. ()

() - ,
3.4.11-19; 3.4.21-24; 3.4.99), - (-
- 1962 () [7, 55].

[7].

% () : = 1:3 0,5-1 % (5
— 30-35

[3,5, 43].

[1].

30 () [1].

[3].

[1].

(),

(),

() (rheumatoid arthritis)

[1, 56].

[1, 3].

[51,52].

(),

.),

(;

[1,3].

(70 %),

[30, 42, 44, 54, 59].

[33].

24 MMQ,

[20]. MM (), [34,60,61].

C- , MM -23 MM^26) [20, 45]. (Hidalgo ,, [25].

: (-1, -8, -13), (-2, -9),

(T M),

[30-32].

[46].

(-1),

T M 1- ,

25%

I, II, III, V IX

[7],

-1

1

[7,38].

[22].

[5].

IV

[27].

[39-41].

[57]

[26, 28].

Ende et al.

MM^2 -9 [21].

[11-13].

Ji H.T. et al. [29].

MM -7,-14 -16 in vitro [48-50].

MM , MM^-7.

[2, 9].

MMQ.

70 M (EC50) 9 59
MM^2 /5- -9, 4

7

16 (HPV16)

(HPV)

HPVI6 HPV18

[5, 8,10,].

HPV

[5- 7, 56-58].

HPV

2008

500

- proliferation and in vitro angiogenesis / T. Fotsis, M.S. Pepper, E. Aktas et al. // *Cancer Res.* 1997.-Vol. 57.- P. 2916-2921.
24. Furge K.A. Met receptor tyrosine kinase: enhanced signaling through adapter protein / K.A. Furge, Y.W. Zhang, G.F. Vande Woude // *Oncogene* 2000.-Vol. 19.-P. 5582-5589.
25. Hidalgo M., Eckhardt S. G., Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy J. Natl. Cancer Inst., 2001.-Vol. 93, N3.-P. 178-193
26. Hou DX. Molecular mechanisms behind the chemopreventive effects of anthocyanidins / D.X. Hou, M. Fujii, N. Terahara, M. Yoshimoto // *JBiomedBiotechnol* 2004.-Vol.5.-P. 321-325.
27. Hou Y. Luteolin inhibits proliferation and affects the function of stimulated rat synovial fibroblasts / Y. Hou, J. Wu, Q. Huang, L. Guo // *Cell Biol Int.* 2009.-Vol. 33, N2.-P. 135-147.
28. Huang Y.T. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor / Y.T. Huang, J.J. Hwang, P.P. Lee et al. // *Br. J. Pharmacol.* 1999.- Vol. 128.-P. 999-1010.
29. Ji H.T. Inhibition of matrix metalloproteinases activities by luteolin / H.T. Ji, X.J. Shi, Y. Hong et al. // *Chem. Res. Chin. Univ.* 2009.- Vol. 25, N6.- P. 895-898.
30. Kim M.H. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases / M.H. Kim // *J. Cell Biochem.* 2003.- Vol. 89.- P. 529-538.
31. Kimata M. Effects of luteolin and other flavonoids on IgE-mediated allergic reaction / M. Kimata, N. Inagaki, H. Nagai // *Planta Med.* 2000.- Vol. 66.- P. 25-29.
32. Kinoshita T. Construction of a novel database for flavonoids / T. Kinoshita, Z. Lepp, H. Chuman // *J Med Inv* 2005;52:Suppl:291:2.
33. Ko W.G. Effects of luteolin on the inhibition of proliferation induction of apoptosis in human myeloid leukaemia cells / W.G. Ko, T.H. Kang, S.J. Lee et al. // *Phytother. Res.* 2002.- Vol. 16.-P. 295-298.
34. Lee H.J. Induction apoptosis of luteolin in human hepatoma HepG2 cells involving mitochondria translocation of Bax/Bak and activation of JNK / H.J. Lee, C.J. Wang, H.C. Kuo et al. // *Toxicol. Appl. Pharmacol.* 2005.-Vol. 203.- P. 124-131.
35. Lee L.T. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells / L.T. Lee, Y.T. Huang, J.J. Hwang et al. // *Anticancer Res.* 2002.- Vol. 22.- P. 1615-1627.
36. Lee W.J. Inhibitory effect of luteolin on hepatocyte growth factor/scatter factor-induced HepG2 cell invasion involving both MAPK/ERKs and PI3K-Akt pathways / W.J. Lee, L.F. Wu, W.K. Chen et al. // *Chem-Biol. Interactions.*-2006.- Vol. 160.-P. 123-133.
37. Manthey J.A. Antiproliferative activities of citrus against six human cancer cell lines / J.A. Manthey, N. Guthrie // *J. Agric. Food Chem.* 2002.- Vol. 50.- P. 5837-5843.
38. Marchand L.L. Cancer preventive effects of flavonoids—a review / L.L. Marchand // *Biomed. Pharmacother.* 2002.- Vol. 56.- P. 296-301.
39. Matrislan L.M. Metalloproteinases and their inhibitors in matrix Remolding / L.M. Matrislan // *Trends Genet.* 1990.- Vol. 6.- P. 121-125.
40. Mittra B. Luteolin, an abundant dietary component is a potent anti-leishmanial agent that acts by inducing topoisomerase II-mediated kinetoplast DNA cleavage leading to apoptosis / B. Mittra, A. Saha, A.R. Chowdhury // *Mol. Med.* 2000.- Vol. 6.-P. 527-541.
41. Nagase H. Jr Matrix metalloproteinases. / H. Nagase, J.F. Woessner // *J Biol Chem.* 1999.-Vol. 274.-P. 21491-21494.
42. Nijveldt R.J., Flavonoids: a review of probable mechanisms of action and potential applications. / R.J. Nijveldt van Nood E., van Hoorn D.E.C. et al. // *Am J Clin Nutr* 2001;74:418—425
43. Oh J. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis / J. Oh, R. Takahashi, S. Kondo et al. // *Cell.* 2001.-Vol. 107, N6.-P. 789-800.
44. Overall C.M. Strategies for MMP inhibition in cancer: / C.M. Overall, C. Lopez-Otin // *Nat. Rev. Can.,* 2002,-Vol. 2.- P. 657-672
45. Pavlaki M. Matrix metalloproteinase inhibitors (MMPi): The beginning of phase I or the termination of phase III clinical trials / M. Pavlaki, S. Zucker // *Cancer Metastasis Reviews.* 2003.-Vol. 22.- P. 177-203.
46. Qutub A., Multiscale models of angiogenesis / A. Qutub, Gabhann, Karagiannis et al. // *F.IEEE Eng Med Biol Mag* 2009;28:2:14-31.
47. Sang Q.-X.A. Matrix metalloproteinase inhibitors as protective agents for the prevention and treatment of cardiovascular and neoplastic diseases / Q.-X.A. Sang, Y. Jin, R.G. Newcomer et al. // *Curr. Topics Med. Chem.* 2006.- Vol. 6.-P. 289-316.
48. Schneider M.R. Antimetastatic prostacyclin analogs / M.R. Schneider, M.R. Chneider, M. Schirner // *Drug Future* 1993.-Vol. 18.- P. 29-48.
49. Shimoi K. Metabolic fate of luteolin and its functional activity at focal site / K. Shimoi, N. Saka, K. Kaji et al. // *BioFactors.* 2000.- Vol. 12, N1-4.-P. 181-186.
50. Sim G.-S. Structure activity relationship of antioxidative property of flavonoids and inhibitory effect on matrix metalloproteinase activity in UVA-irradiated human dermal fibroblast / G.-S. Sim, B.C. Lee, H.S. Cho // *Arch. Pharm. Res.* 2007.- Vol. 30, N3.-P. 290-298.
51. Specific Herbs for Arthritis // <http://www.livestrong.com/article/104197-specific-herbs-arthritis/>
52. Stewart J.R. Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism / J.R. Stewart, N.E. Ward, Ioannides, C.A. O'Brain // *Biochemistry* 1999;38:13244—13251.
53. Sulkala M. Matrix metalloproteinases (MMPs) in the dentin-pulp complex of healthy and carious teeth.- Diss.- Oulu, Finland.- 2004.- 78p.
54. Thomas N.V. Metalloproteinase Inhibitors: Status and Scope from Marine Organisms / N.V. Thomas, S.K. Kim // *Biochemistry Research International.*- 2010.- Vol. 2010.- P. 1-10
55. Ueki T. Expression of hepatocyte growth factor and its receptor, the cmet proto-oncogene, in hepatocellular carcinoma / T. Ueki, J. Fujimoto, T. Suzuki et al. // *Hepatology* 1997.- Vol. 25.-P. 619-623.
56. Xagorari A. Luteolin Inhibits an Endotoxin-Stimulated Phosphorylation Cascade and Proinflammatory Cytokine Production in Macrophages / A. Xagorari, A. Papapetropoulos, A. Mauromatis et al. // *J. Pharmacol. Exp. Ther.*.-2001.- Vol. 296.-P. 181-187
57. Yoned A.J. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice / A.J. Yoned, H. Kuniyasu, M.A. Crispens et al. // *J. Natl. Cancer. Inst.* 1998.-Vol. 90.- P. 447-454.
58. Zitka O. Matrix Metalloproteinases / O. Zitka, J. Kukacka, S. Krizkov // *Current Medicinal Chemistry,* 2010 Vol. 17, N 31.-P. . 3751-3768(18
59. Watson S.A. Inhibition of organ invasion by the metalloproteinase inhibitor Batimastat (BB-94) in two human colon carcinoma metastasis models / S.A. Watson, T.M. Morris, G. Robinson // *Cancer Res.* 1995.- Vol. 55.- P. 3629-3633.
60. Weyand C.M., Goronzy J.J. Pathogenesis of rheumatoid arthritis... / C.M. Weyand, J.J. Goronzy // *Med Clin North Am* 1997.- Vol. 81.-P. 29-55.

615.32:547.814.5_

.. . ; . . ,
.. . ; . .

()

